BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Company plans to initiate trial following recent meeting with FDA
In a significant development aimed at addressing the growing challenges associated with agitation in patients suffering from Alzheimer’s dementia, BioXcel Therapeutics has revealed its plan for the TRANQUILITY In-Care Pivotal Phase 3 Trial with the experimental drug BXCL501. The announcement comes on the heels of a recently held meeting between the company and the United States Food and Drug Administration (FDA).
Alzheimer’s dementia is a devastating neurodegenerative disease that not only affects memory and cognitive abilities but also leads to behavioral and psychological symptoms such as agitation. This agitated state is commonly characterized by restlessness, irritability, aggression, and emotional distress, adding to the burden faced by patients, caregivers, and healthcare providers. BioXcel Therapeutics recognizes the urgent need for effective pharmacological interventions to manage agitation in Alzheimer’s patients and has dedicated its resources to develop a potential solution through BXCL501.
BXCL501 is an investigational, orally-disintegrating, non-hallucinogenic, selective alpha 2a-adrenergic receptor agonist. This experimental drug has shown promising results in earlier phases of clinical trials in reducing agitation associated with various psychiatric disorders. The upcoming TRANQUILITY trial aims to evaluate the safety and efficacy of BXCL501 specifically for agitation in Alzheimer’s dementia patients. Through this phase 3 trial, BioXcel Therapeutics seeks to gather robust clinical evidence to support the potential approval of BXCL501 as a novel therapeutic option.
Following a productive discussion with the FDA, BioXcel Therapeutics has charted out a meticulous plan for the TRANQUILITY trial, ensuring a comprehensive evaluation of BXCL501. The trial will focus on patients with moderate to severe agitation associated with Alzheimer’s dementia, utilizing a randomized, double-blind, placebo-controlled design to assess the effectiveness of BXCL501 compared to a placebo. Additionally, important secondary endpoints such as patient-reported outcomes, caregiver burden, and safety will also be evaluated, aiming to provide a holistic understanding of BXCL501’s profile.
The initiation of the TRANQUILITY trial marks a significant milestone in the journey towards addressing agitation in patients suffering from Alzheimer’s dementia, potentially paving the way for a groundbreaking treatment option. Dr. Vincent Ossipov, Chief Medical Officer at BioXcel Therapeutics, expressed his confidence in the potential of BXCL501 and the positive impact it can have on patients’ lives, stating, We believe BXCL501 has the potential to address a major unmet medical need and are enthusiastic about the initiation of this pivotal trial. The company anticipates the trial to commence in the near future, subject to final regulatory approvals and site activations.
The announcement of BioXcel Therapeutics’ Phase 3 trial plan for BXCL501 brings renewed hope for patients, their families, and healthcare professionals involved in managing the challenges of agitation in Alzheimer’s dementia. As the trial progresses, the medical community eagerly awaits the outcomes that could transform the treatment paradigm for this debilitating symptom. The TRANQUILITY trial serves as a testament to the dedication and perseverance of organizations like BioXcel Therapeutics in their pursuit of innovative therapies that have the potential to significantly improve the lives of Alzheimer’s patients.
Comments